Melanotan II — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Melanotan II

Also known as: MT-II, MTII, Barbie drug, tanning jab, melanotan-II

Synthetic cyclic heptapeptide; non-selective melanocortin receptor agonist; alpha-melanocyte-stimulating hormone (α-MSH) analogue

Research chemicalLast updated: October 31, 2026Based on 37 peer-reviewed studies

What it is

Melanotan II is a peptide people use for sunless tanning and to enhance sexual function. It works by activating receptors that control skin pigmentation and arousal. Not FDA-approved; classified as an experimental unapproved drug; sold as a gray-market research compound with significant safety concerns from unsupervised use.

The scientific side

Melanotan II (MTII) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) with the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 α-MSH(4-10)-NH2. It acts as a potent, non-selective agonist at melanocortin receptors (MCRs), including MC1R, MC3R, and MC4R. At MC1R on melanocytes, it stimulates eumelanin production, resulting in skin pigmentation independent of sun exposure. Via MC4R and MC3R in the central nervous system, it induces spontaneous penile erections and sexual stimulation, modulates energy homeostasis and food intake, promotes oxytocin release from the hypothalamic paraventricular nucleus, and can induce thermogenesis via sympathetic signalling to brown adipose tissue. MTII also activates the hypothalamic-pituitary-adrenal (HPA) axis and induces wakefulness via paraventricular hypothalamic vasopressin neurons projecting to lateral hypothalamic orexin neurons. In vitro and animal data suggest MC1R-mediated upregulation of PTEN and inhibition of COX-2/PGE2 signalling as a potential anti-melanoma mechanism.

Class: Synthetic cyclic heptapeptide; non-selective melanocortin receptor agonist; alpha-melanocyte-stimulating hormone (α-MSH) analogue

Administration & storage

Administration
Subcutaneous injection — used in Phase I and controlled clinical trials (PMID: 863740296798841101862211035391)Subcutaneous injection — reported in toxicity case reports and case series of self-administration (PMID: 231212063305201529451671)Subcutaneous injection (abdominal) — priapism case report (PMID: 30796078)Intraperitoneal injection — animal studies (PMID: 39442746)Intra-nucleus accumbens microinjection — animal studies (PMID: 36155088)Third-cerebroventricular injection — animal studies (PMID: 16166222)Nasal spray — reported in case of mucosal malignant melanoma (PMID: 40210573)Topical application — melanoma mouse model (PMID: 31968661)
Storage
No storage conditions for Melanotan II are described in the reviewed abstracts. Empty string provided; see no_data_topics.
Cautions
Illicitly sourced Melanotan II preparations have been found to have only 30% purity; the wrong active ingredient, wrong dosage, or absence of active ingredient have been documented in seized samples.,Self-administration of 6 mg (described by the patient as six times the recommended starting dose) caused sympathomimetic toxicity, rhabdomyolysis (peak CPK 17,773 IU/L), and renal dysfunction requiring ICU admission.,Melanotan II use has been associated with acute ischemic priapism requiring surgical intervention; this potentially life-altering complication has been reported multiple times in the literature.,Use has been associated with new-onset eruptive/dysplastic melanocytic nevi, darkening of existing nevi, and reports of melanoma emerging during or shortly after use; causality not definitively established but clinicians are advised to be vigilant.,Nasal spray formulation has been reported in association with a case of mucosal malignant melanoma in a 22-year-old female; product is unlicensed and its sale is illegal in the UK and many other countries.,Oral/gingival mucosal pigmentation has been reported following self-injection; gingival pigmentation persisted at 3-month follow-up after discontinuation.,Renal infarction, rhabdomyolysis, and renal failure have been reported; thrombotic pharmacological influence and possible direct toxic renal parenchyma toxicity must be considered.,Use of unregulated preparations carries risks of product contamination, manufacturing impurities, inaccurate dosing, and transmission of infectious diseases.,Sterile technique is essential for any injectable; unregulated sourcing dramatically increases infection risk.

Legal & regulatory status

US FDA

Not approved by the FDA; classified as an unapproved experimental drug. Historically investigated in Phase I/II clinical trials for tanning and erectile dysfunction, but not approved for any indication.

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification